TAVR is where a valve is placed into the heart via a catheter (usually inserted through the leg) to replace the aortic valve, eliminating the need for open-heart surgery.
Admedus’ new TAVR device is designed to reduce the risks associated with the insertion and placement of the valve.
Underpinned by its clinically-superior ADAPT® tissue technology, Admedus’ TAVR aims to set a new benchmark in cardiovascular science and engineering.
The device will be looking to make an impact in the $3.5 billion market which is predicted to reach $5 billion by 2020.
The patent lodgements follow on from Admedus recently entering into an agreement with a renowned European reference laboratory to commence the first TAVR animal trials in July.
Admedus’s CEO Wayne Paterson said: “As I’ve said previously, with this project Admedus wants to set a new global standard in innovation and patient care, built on the absolute cutting-edge of medical science and engineering.”
“With the design of each component, we are addressing vast areas of unmet need in durability, position and placement, cost-efficiency and improved patient outcomes - literally developing novel IP from one tip of the TAVR device to other.
“This is what makes the filing of these patent applications so critically important, we need to protect our significant investment and IP as competitors become increasingly aware of, and interested in, our progress.
“We’re creating something special here, and the competition knows it.”